Image
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Back to top
Prof Diamant Thaçi
Director and Professor at the Institute and Comprehensive Centre for Inflammation Medicine
Professor Diamant Thaçi is Director and Professor at the Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Germany. Professor Thaçi is also Chairman of the Inflammatory Board at the University Hospital Schleswig-Holstein, Lübeck Campus.
He is an active member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Psoriasis Council (IPC), the International Eczema Council (IEC), and the Skin Inflammation & Psoriasis International Network (SPIN). His research interests cover immunological work in basic research and all stages of clinical drug development, with a focus on chronic inflammatory skin diseases.
0 resources
Video3 minutes watch
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
EU-DA-2400650
Video3 minutes watch
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
EU-DA-2400669
Video2 minutes watch
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
EU-DA-2400668
Video2 minutes watch
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
EU-DA-2400666
Video1 minute watch
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.
EU-DA-2400662